PL3808774T3 - Przeciwciało wiążące ludzki il-4r, jego fragment wiążący antygen i ich zastosowanie medyczne - Google Patents

Przeciwciało wiążące ludzki il-4r, jego fragment wiążący antygen i ich zastosowanie medyczne

Info

Publication number
PL3808774T3
PL3808774T3 PL19852040.5T PL19852040T PL3808774T3 PL 3808774 T3 PL3808774 T3 PL 3808774T3 PL 19852040 T PL19852040 T PL 19852040T PL 3808774 T3 PL3808774 T3 PL 3808774T3
Authority
PL
Poland
Prior art keywords
human
medical use
antigen binding
binding fragment
antibody
Prior art date
Application number
PL19852040.5T
Other languages
English (en)
Inventor
Cheng LIAO
Zupeng XU
Jiahua JIANG
Lianshan Zhang
Xueming Qian
Fei TENG
Original Assignee
Jiangsu Hengrui Medicine Co., Ltd.
Shanghai Hengrui Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd. filed Critical Jiangsu Hengrui Medicine Co., Ltd.
Publication of PL3808774T3 publication Critical patent/PL3808774T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL19852040.5T 2018-08-24 2019-08-23 Przeciwciało wiążące ludzki il-4r, jego fragment wiążący antygen i ich zastosowanie medyczne PL3808774T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201810971269 2018-08-24
CN201811472752 2018-12-04
CN201910221311 2019-03-22
CN201910401923 2019-05-15
PCT/CN2019/102169 WO2020038454A1 (zh) 2018-08-24 2019-08-23 结合人il-4r的抗体、其抗原结合片段及其医药用途

Publications (1)

Publication Number Publication Date
PL3808774T3 true PL3808774T3 (pl) 2025-06-23

Family

ID=69591987

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19852040.5T PL3808774T3 (pl) 2018-08-24 2019-08-23 Przeciwciało wiążące ludzki il-4r, jego fragment wiążący antygen i ich zastosowanie medyczne

Country Status (14)

Country Link
US (1) US12162944B2 (pl)
EP (1) EP3808774B1 (pl)
JP (1) JP7405831B2 (pl)
KR (1) KR102840973B1 (pl)
CN (2) CN112513090B (pl)
AU (1) AU2019324403B2 (pl)
BR (1) BR112021002989A2 (pl)
CA (1) CA3105527A1 (pl)
ES (1) ES3028305T3 (pl)
MX (1) MX2021001143A (pl)
MY (1) MY205774A (pl)
PL (1) PL3808774T3 (pl)
TW (1) TWI840399B (pl)
WO (1) WO2020038454A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113527485B (zh) * 2020-04-17 2024-11-15 湖南麦济生物技术股份有限公司 抗人白细胞介素-4受体α抗体及其制备方法和应用
CN111996172A (zh) * 2020-09-08 2020-11-27 中国食品药品检定研究院 一种用于测定il-4靶向治疗性抗体生物学活性的方法
TWI925918B (zh) * 2020-12-22 2026-05-21 大陸商江蘇恆瑞醫藥股份有限公司 抗il-4r抗體或其抗原結合片段的複合物及醫藥用途
CN114652853B (zh) * 2020-12-22 2024-09-13 江苏恒瑞医药股份有限公司 抗il-4r抗体-药物偶联物及医药用途
EP4470569A1 (en) 2022-01-29 2024-12-04 Shanghai Shengdi Pharmaceutical Co., Ltd Drug conjugate of glucocorticoid
EP4518837A1 (en) 2022-05-02 2025-03-12 Regeneron Pharmaceuticals, Inc. Anti-interleukin-4 receptor (il-4r) antibody formulations
EP4518839A2 (en) 2022-05-02 2025-03-12 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity
CA3268111A1 (en) * 2022-09-22 2024-03-28 Biosion Inc. Recombinant bispecific antibodies targeting TSLP and IL4R
US20240360232A1 (en) * 2023-03-22 2024-10-31 Sanofi Biotechnology Methods for treating chronic obstructive pulmonary disease (copd) by administering an il-4r antagonist
TW202506196A (zh) 2023-07-28 2025-02-16 大陸商江蘇恒瑞醫藥股份有限公司 含有糖皮質激素的抗體藥物偶聯物的藥物組合物
AU2024373307A1 (en) 2023-11-02 2026-05-14 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
AU2024385129A1 (en) * 2023-11-22 2026-06-11 The United Bio-Technology (Hengqin) Co., Ltd. ANTI-IL-4Rα ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND BISPECIFIC ANTIBODY AND USE THEREOF
CN117924490B (zh) * 2023-12-22 2024-10-22 华润生物医药有限公司 抗il-4r抗体及其用途
CN117924491B (zh) * 2023-12-22 2024-10-18 华润生物医药有限公司 抗il-4r抗体及其用途
US20260070995A1 (en) 2024-09-09 2026-03-12 Marcella Ruddy Methods for treating bullous pemphigoid by administering an il-4r antagonist
WO2026151982A1 (en) 2025-01-10 2026-07-16 Regeneron Pharmaceuticals, Inc. Methods of treating food allergy by administering an il-4r antagonist and a bcma targeting agent

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2990420T (pt) 2000-05-26 2017-03-16 Immunex Corp Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CA2664343C (en) 2006-10-02 2016-04-26 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
MX2010006735A (es) * 2007-12-21 2010-09-30 Medimmune Ltd Miembros de union para receptor alfa de interleucina-4 (il-4ra) - 173.
RU2691698C2 (ru) * 2012-02-24 2019-06-17 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Антитела против sez6 и способы их применения
KR102502640B1 (ko) 2012-08-21 2023-02-23 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
CN106604744A (zh) 2014-09-03 2017-04-26 免疫医疗有限公司 稳定的抗IL‑4R‑α抗体配制品
EP3954710A3 (en) * 2015-04-02 2022-07-20 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
CN108339118A (zh) * 2017-01-23 2018-07-31 瑞阳(苏州)生物科技有限公司 治疗或预防阻塞性睡眠呼吸暂停的药物组合物
CN108409860B (zh) * 2017-02-10 2021-10-15 三生国健药业(上海)股份有限公司 抗人白细胞介素-4受体α单克隆抗体、其制备方法和应用
CN108373505B (zh) * 2018-04-20 2019-08-20 北京智仁美博生物科技有限公司 抗il-4r抗体及其用途

Also Published As

Publication number Publication date
MX2021001143A (es) 2021-04-12
BR112021002989A2 (pt) 2021-05-11
CN112513090B (zh) 2023-03-10
AU2019324403B2 (en) 2026-05-14
EP3808774A4 (en) 2021-08-18
US20210238294A1 (en) 2021-08-05
US12162944B2 (en) 2024-12-10
JP7405831B2 (ja) 2023-12-26
KR20210049792A (ko) 2021-05-06
JP2021533792A (ja) 2021-12-09
MY205774A (en) 2024-11-12
CA3105527A1 (en) 2020-02-27
KR102840973B1 (ko) 2025-07-30
TWI840399B (zh) 2024-05-01
CN112513090A (zh) 2021-03-16
EP3808774A1 (en) 2021-04-21
WO2020038454A1 (zh) 2020-02-27
AU2019324403A1 (en) 2021-01-28
TW202023612A (zh) 2020-07-01
ES3028305T3 (en) 2025-06-18
EP3808774B1 (en) 2025-04-16
CN115991781A (zh) 2023-04-21
EP3808774C0 (en) 2025-04-16

Similar Documents

Publication Publication Date Title
EP3689909A4 (en) Tigit antibody, antigen-binding fragment thereof, and medical use thereof
SG11202107007VA (en) Antibody against human il-4ra and use thereof
EP3632932A4 (en) ANTI-CD40 ANTIBODIES, ANTIGEN BINDING FRAGMENT OF THIS ANTIGEN AND ASSOCIATED MEDICAL USE
EP3892634A4 (en) ANTI-CD40 ANTIBODIES, ANTIGEN BINDING FRAGMENT AND PHARMACEUTICAL USE THEREOF
IL279015A (en) Anti-interleukin-17A antibody, its pharmaceutical preparation and its use
ZA202104518B (en) Cd3 antibody and pharmaceutical use thereof
ZA202006904B (en) Anti-il-4r antibody and use thereof
ZA201700528B (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
IL275243A (en) Bispecific antigen-binding molecules that bind leptin and/or GP130 receptor and methods of using them
DK3638698T3 (da) Anti-TMPRSS2-antistoffer og antigenbindingsfragmenter
SG11202100746WA (en) Anti-tigit antibody and use thereof
IL290551A (en) Antibodies against ilt2 and their use
EP3808774A4 (en) HUMAN IL-4R BINDING ANTIBODY, ANTIGBINDING FRAGMENT THEREOF AND ITS MEDICAL USES
ZA202004907B (en) Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
EP3778636A4 (en) ANTI-CD27 ANTIBODIES, ANTIGEN BINDING FRAGMENT AND ASSOCIATED MEDICAL USE
EP3378871A4 (en) PD-L1 ANTIBODY, ANTIGEN FRAGMENT FOR BINDING THEREOF AND PHARMACEUTICAL USE THEREOF
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
WO2017123636A8 (en) Dosage and administration of anti-c5 antibodies for treatment
PT4082570T (pt) Anticorpo anti-ctla-4 e a sua utilização
SG11202011201QA (en) Fully human antibodies against ox40, method for preparing same, and use thereof
EP3587452A4 (en) ANTI-TIM-3 ANTIBODIES, ANTIGEN BINDING FRAGMENT OF IT, AND MEDICAL USES OF IT
EP3733703A4 (en) Isolated antibody or antigen binding fragment thereof and use of same in tumor treatment
IL291082A (en) Anti-vsig4 antibody or antigen-binding fragment and uses thereof
EP4006055A4 (en) ANTI-BCMA ANTIBODIES, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF
ZA202001807B (en) Il-5 antibody, antigen binding fragment thereof, and medical application therefor